XLO — Xilio Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $38.84m
- -$16.45m
- $6.34m
Annual income statement for Xilio Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 6.34 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 54.6 | 75 | 89.1 | 79.1 | 66.9 |
| Operating Profit | -54.6 | -75 | -89.1 | -79.1 | -60.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -55.2 | -75.8 | -88.2 | -76.4 | -58.2 |
| Net Income After Taxes | -55.2 | -75.8 | -88.2 | -76.4 | -58.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -55.2 | -75.8 | -88.2 | -76.4 | -58.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -55.2 | -75.8 | -88.2 | -76.4 | -58.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.07 | -2.84 | -3.22 | -2.78 | -1.07 |
| Dividends per Share |